HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deanna Kamienski

Senior Deals Analyst, Biomedtracker

Deanna has been tracking deal-making activity in the biopharma and medtech industries since 2000. She is currently a Senior Deals Analyst for Biomedtracker and had previously contributed to the Strategic Transactions deals database. Deanna authors a Quarterly Statistics article and other monthly trend pieces for In Vivo. She holds a Bachelor of Science degree from the University of Vermont..

Latest From Deanna Kamienski

Deals In Depth: January 2021

BeiGene and Novartis penned a potential $2.2bn collaboration for the development, manufacture, and commercialization of BeiGene’s humanized IgG4 anti-PD-1 monoclonal antibody tislelizumab in the US, Canada, Mexico, member countries of the EU, the UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. Steris entered into a definitive agreement to acquire Cantel Medical, a global provider of infection prevention products and services primarily to endoscopy and dental customers. The total enterprise value of the deal is estimated at $4.6bn. Financing reached $10.5bn in biopharma, $984m in device, and $2.7bn in diagnostics.

Deals Market Intelligence

Financing: 2020 Ends On A High Note For Medtech

During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.

Commercial Companies

Dealmaking Quarterly Statistics, Q4 2020

During Q4, biopharma merger and acquisition value reached $73.9bn and drew in $54.5bn in potential deal value from alliances. Device company M&A values reached $5.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $3.3bn.

Deals Market Intelligence

Financing Quarterly Statistics, Q4 2020

During Q4, biopharmas brought in an aggregate $53.5bn in financing and device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.

Deals BioPharmaceutical

Deals In Depth: December 2020

Merck KGaA and Artios penned a global three-year strategic research collaboration to discover and develop multiple precision oncology drugs. The deal could be worth close to $7bn for four-year-old Artios. AstraZeneca announced a definitive agreement to acquire public rare disease drug developer Alexion for approximately $39bn. This was 2020’s largest M&A. Financing reached $28bn in biopharma, $879m in device, and $2.4bn in diagnostics.

Deals Market Intelligence

Deals In Depth: November 2020

Biogen and Sage Therapeutics penned a potential $3.1bn global collaboration for Sage’s zuranolone (SAGE-217) for major depressive disorder, postpartum depression and other psychiatric disorders, and SAGE-324 for essential tremor and other neurological disorders. In the month’s top M&A, Merck agreed to acquire privately held VelosBio for $2.75bn in cash. VelosBio is developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1. Financing reached $12.8bn in biopharma, $2.9bn in device, and $2bn in diagnostics.

Analysis Deals
See All
UsernamePublicRestriction

Register